China’s Licensing Trends Shaping Global Drug Development: Strategic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Over the past five years, China’s biotech sector’s out-licensing deals have increased significantly.
Between 2020 and 2024, the compound annual growth rate (CAGR) was approximately 21.7% for licensing agreements, which is a significant increase highlighting the strength of innovative drugs coming from China.
This can be attributed to accelerated regulatory reforms, resulting in streamlined drug approvals and extended market exclusivity.
Oncology accounted for 59% of these deals and made up 52% of the total deal value during this time period.
Other therapy areas such as immunology and metabolic disorders have also had interest, accounting for 13% and 8% of deal activity, respectively.
Out-licensing deals associated with mAbs had a total of 46 deals accounting for 36% between 2020–25 with a deal value of $45 billion. Small molecules followed with 32 deals accounting for 25%, with a deal value of $42 billion.
Antibody-drug conjugates (ADCs) had fewer deals than mAbs and small molecules with a total of 31 deals (24%) and accounted for a deal value of $40 billon over the 5-year period.
AstraZeneca led big pharma with the most out-licensing deals between 2020 and 2025 YTD, with nine deals valued at approximately $20 billion.
Activity in 2025 was prevalent, with six of the top 10 deals since 2020 occurring during this year.
The Chinese parent companies benefitted from upfront payments for R&D, gaining equity in novel Chinese therapeutics.
As a result, all parties involved have the potential to gain a significant return on their initial investment.

Scope

This report examines the regulatory initiatives that the Chinese government have implemented in the last decade to accelerate the out-licensing landscape in China. The analysis focuses on the surge in out-licensing deals due to China’s strengthened R&D capabilities, leading out-licensing deals by therapy areas and modalities, the increased activity between China and bigpharma, and Chinese regulatory reforms to streamline international collaboration.

Table of Contents

Executive Summary

Introduction

China’s Out-Licensing Deals

China’s Out-Licensing Deals by Therapy Area

China’s Out-Licensing Deals by Modality

China’s Out-Licensing Deals with Big Pharma

China’s Out-Licensing Deals Structure with Big Pharma

China’s NewCo Model

Key Takeaways

Appendix:

– Abbreviations

– Related Reports

– Authors

– Contact us

China’s Licensing Trends Shaping Global Drug Development: Strategic Intelligence thematic reports
Currency USD
$2,950

Can be used by individual purchaser only

$8,850

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

China’s Licensing Trends Shaping Global Drug Development: Strategic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at China’s Licensing Trends Shaping Global Drug Development: Strategic Intelligence in real time.

  • Access a live China’s Licensing Trends Shaping Global Drug Development: Strategic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.